Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Secondary malignancies

G Socié1

  • 1Service d'Hématologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France.

Current Opinion in Hematology
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Secondary malignancies, including leukemia, lymphoma, and solid tumors, are a growing concern for patients surviving stem cell transplantation. This review highlights recent clinical and biologic data on these post-transplant cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Severe corneal manifestations of graft-versus-host disease: Experience of a tertiary referral center.

The ocular surface·2024
Same author

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021
Same author

Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Leukemia·2021
Same author

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Leukemia·2020
Same author

FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study.

Bone marrow transplantation·2020
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Increasing survival rates post-stem cell transplantation lead to focus on long-term complications.
  • Malignant diseases represent a significant concern for long-term survivors.
  • Secondary malignancies are a critical area of research in transplantation.

Purpose of the Study:

  • To review recent clinical and biologic data on secondary malignancies after stem cell transplantation.
  • To emphasize findings from the past 12-month review period.
  • To provide a comprehensive summary of post-transplant cancers.

Main Methods:

  • Systematic review of recent literature on secondary malignancies.
  • Focus on articles published within the last 12 months.

Related Experiment Videos

  • Inclusion of data on both allogeneic and autologous stem cell transplantation.

    • Main Results:

    • Summary of recent clinical data on secondary leukemia, lymphoma, and solid tumors.
    • Analysis of recent biologic data related to post-transplant malignancies.
    • Identification of trends in secondary cancer development post-transplantation.

    Conclusions:

    • Secondary malignancies are an important clinical issue in stem cell transplant survivors.
    • Ongoing research is crucial for understanding and managing these cancers.
    • Further investigation into the biology and treatment of post-transplant malignancies is warranted.